Phase 3 Schizophrenia Trial, Recruiting NCT06482554 Sponsor: Louisiana State University Health Sciences Center Shreveport Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT06482554
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or a related psychotic disorder.
  • People who score above 35 on a symptom rating scale called the BPRS at the initial screening visit.
  • People who score above 32 on an apathy rating scale called the AES-C at the initial screening visit.
  • People whose current treatment plan (including any medications, supplements, or probiotics) has remained unchanged for at least 30 days before screening.
  • People who, in the trial doctor's opinion, are able to attend all scheduled visits and are likely to complete all required assessments.
  • People who speak and understand English, as all consent forms and assessments are conducted in English.
  • People who are willing to take a urine drug screen and return a negative result.
  • Women who could become pregnant must not currently be pregnant or breastfeeding, must have a negative urine pregnancy test, and must agree to use an accepted form of birth control (including abstinence) during the trial and for 30 days after the last dose of the study drug. This requirement also applies to men who could father a child.

Who may not be able to join:

  • People who score below 35 on the BPRS rating scale at the screening visit.
  • People who score below 32 on the AES-C rating scale at the screening visit.
  • People with a significant medical condition or an unstable illness that, in the trial doctor's opinion, would prevent safe participation.
  • People currently taking more than one antipsychotic medication.
  • People currently receiving a long-acting injectable medication for psychotic symptoms.
  • People with a substance use disorder, or whose urine drug screen shows a positive result for stimulants.
  • Women who are pregnant or who could become pregnant without having measures in place to prevent pregnancy.
  • People who have been diagnosed with dementia.
  • People with an intellectual disability or level of cognitive difficulty that would, in the trial doctor's opinion, affect the ability to complete the symptom or apathy assessments.
  • People who have been diagnosed with Parkinson's disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Shawn McNeil, MD, LSU Health Shreveport

Phone: 318-675-7065

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Louisiana State University Health Sciences Center Shreveport
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in AES-C Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov